Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05897684
Other study ID # CS-AVA-2022-0016
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date September 11, 2023
Est. completion date December 1, 2030

Study information

Verified date May 2024
Source Vifor Fresenius Medical Care Renal Pharma
Contact Avacostar Study Team
Phone +41 58 851 80 00
Email clinicaltrials@cslbehring.com
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The Avacostar PASS is a non-interventional, multi-national, prospective cohort study that will collect data from 2 cohorts of patients: those treated with avacopan for active severe AAV, and a second cohort treated with a cyclophosphamide or rituximab-based induction regimen without avacopan for active severe AAV. The overall study duration is anticipated to be up to 7 years, including a recruitment period of approximately 3 years.


Description:

The Avacostar PASS is a non-interventional, multi-national, prospective cohort study that will collect data from 2 cohorts of patients: those treated with avacopan for active severe AAV, and a second cohort treated with a cyclophosphamide or rituximab-based induction regimen without avacopan for active severe AAV. The overall study duration is anticipated to be up to 7 years, including a recruitment period of approximately 3 years. Enrolled patients will be followed until the last patient last visit (LPLV) milestone, which will be 4 years after the last participant is enrolled. Germany and the United Kingdom (UK) have been selected for the study. Additional countries may be considered according to availability of avacopan and suitability for the study. Patients will be enrolled prospectively, but up to 6 months of data may be collected retrospectively if necessary. Baseline visit is defined as the day that induction treatment (avacopan or non-avacopan standard of care (SoC) cyclophosphamide or rituximab) is started for active severe AAV. Patients who started avacopan/SoC induction therapy for active severe AAV within 6 months of the enrolment visit and fulfil eligibility criteria may be enrolled in the PASS. Individual participant follow-up data will be collected periodically at routine clinic visits until the LPLV, which will be 4 years after the last participant is enrolled. The primary objective of the study is: To evaluate the incidence of defined Medical Events of Special Interest (MESIs) in patients with AAV commencing avacopan.


Recruitment information / eligibility

Status Recruiting
Enrollment 500
Est. completion date December 1, 2030
Est. primary completion date December 1, 2030
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Diagnosis of AAV (MPA or GPA), as determined by the Investigator according to their usual practice. - Active, severe AAV at the time of commencing avacopan or non-avacopan SoC induction therapy, in the opinion of the Investigator. - Age =18 years of either sex. - Has provided written informed consent. - Has commenced within the previous 6 months, or is planned to commence avacopan, cyclophosphamide or rituximab for the treatment of severe, active AAV outside of an interventional clinical study. Exclusion Criteria: • Concurrent participation in an interventional study, unless prospectively discussed and agreed with the Medical Monitor.

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
Germany Charité University Medicine Berlin
Germany University Hospital of Cologne Cologne
Germany Municipal Hospital Dresden Dresden
Germany University Hospital Essen Essen
Germany University Hospital Freiburg Freiburg
Germany University Medical Center Göttingen Göttingen
Germany University Hospital Eppendorf Hamburg
Germany KRH Klinikum Siloah Hannover
Germany Rheumazentrum Ruhrgebiet Herne
Germany LMU Munich
Germany Medius Kliniken Plochingen
Germany St. Josef-Stift Sendenhorst Sendenhorst
United Kingdom UHB NHS Foundation Trust Birmingham
United Kingdom Bradford Teaching Hospitals NHS Foundation Trust Bradford
United Kingdom North Bristol NHS Trust Bristol
United Kingdom Addenbrookes Hospital Cambridge
United Kingdom East Kent Hospitals University NHS FT Canterbury
United Kingdom Cardiff and Vale UHB Cardiff
United Kingdom Epsom & St. Helier NHS Trust Carshalton
United Kingdom University Hospitals Coventry and Warwickshire Coventry
United Kingdom Royal Devon University Healthcare NHS Foundation Trust Exeter
United Kingdom NHS Greater Glasgow & Clyde Glasgow
United Kingdom University Hospitals of Leicester NHS Trust Leicester
United Kingdom Barts Health London
United Kingdom Hammersmith Hospital, Imperial College Healthcare NHS Trust London
United Kingdom Kings College Hospital London
United Kingdom Royal Free London
United Kingdom St Thomas' Hospital London
United Kingdom Manchester University NHS Foundation Trust Manchester
United Kingdom Nottingham university hospitals NHS trust Nottingham
United Kingdom Rheumatology Department, Oxford University Hospitals NHS Foundation Trust Oxford
United Kingdom Royal Berkshire NHS foundation trust Reading
United Kingdom Northern Care Alliance Salford
United Kingdom Swansea Bay University LHB Swansea
United Kingdom York & Scarborough Teaching Hospitals NHS FT York

Sponsors (1)

Lead Sponsor Collaborator
Vifor Fresenius Medical Care Renal Pharma

Countries where clinical trial is conducted

Germany,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary To evaluate the incidence of defined MESIs To evaluate the incidence of defined MESIs in patients with AAV commencing avacopan. MESIs include liver injury, cardiac safety, serious infection, and malignancy. up to 7 years
Secondary Incidence rates of AE in the avacopan and non-avacopan groups up to 7 years
Secondary AEs leading to discontinuation of therapy in the avacopan group up to 7 years
Secondary Incidence of SAEs in the avacopan and non-avacopan groups up to 7 years
Secondary Incidence of ADRs in the avacopan group up to 7 years
Secondary Incidence of SADRs in the avacopan group up to 7 years
Secondary Change in eGFR over time in the avacopan and non-avacopan groups up to 7 years
Secondary Change in IgG over time in the avacopan and non-avacopan groups up to 7 years
Secondary Change in CPK over time in the avacopan and non-avacopan groups up to 7 years
Secondary Change in ALT over time in the avacopan and non-avacopan groups up to 7 years
Secondary Change in AST over time in the avacopan and non-avacopan groups up to 7 years
Secondary Change in billirubin over time in the avacopan and non-avacopan groups up to 7 years
Secondary Change in WBC over time in the avacopan and non-avacopan groups up to 7 years
Secondary Change Albumin over time in the avacopan and non-avacopan groups up to 7 years
Secondary Time to first flare over time in the avacopan and non-avacopan groups A flare is defined in the BVAS as a score of more than 0. No flare is defined as a BVAS score equal to 0 up to 7 years
Secondary Change in VDI scores over time in the avacopan and non-avacopan groups up to 7 years
Secondary Incidence of MESIs in the non-avacopan group up to 7 years
Secondary Incidence rates of SAEs and MESIs in the avacopan group compared to the non-avacopan group, up to 7 years
Secondary Incidence rates of MESIs in the avacopan group compared to the non-avacopan group, up to 7 years
Secondary Use of concomitant immunosuppression over time and cumulative by treatment group, up to 7 years
Secondary Duration of GC-free periods up to 7 years
Secondary Proportion of GC-free patients over time by treatment group. up to 7 years
Secondary Duration of treatment with avacopan by reason for treatment discontinuation. up to 7 years
See also
  Status Clinical Trial Phase
Recruiting NCT02257866 - Studies of the Natural History, Pathogenesis, and Outcome of Idiopathic Systemic Vasculitis
Completed NCT02463539 - Residual Anti-pneumococcal Immunity After Pneumococcal Immunization in ANCA-associated Vasculitis N/A
Recruiting NCT05364892 - Biocollection of Patients With ANCA Associated Vasculitis N/A
Terminated NCT00482066 - Abatacept in ANCA Associated Vasculitis Phase 2
Not yet recruiting NCT02126098 - Observation Study of Clinical Manifestation and Outcome in Chinese Patients With Pulmonary Vasculitis N/A
Recruiting NCT05965284 - Efficacy and Safety for Telitacicept in the Remission Maintenance Treatment of ANCA-associated Vasculitis (TTCAZAREM) Phase 4
Recruiting NCT06285279 - FKC288 in Participants With Autoimmune Kidney Diseases Phase 1
Completed NCT02994927 - A Phase 3 Clinical Trial of CCX168 (Avacopan) in Patients With ANCA-Associated Vasculitis Phase 3
Recruiting NCT02463578 - Immunogenicity of a Combined Anti-pneumococcal Vaccine Schedule in Patients With ANCA-associated Vasculitis N/A
Active, not recruiting NCT05716334 - Biosimilars of Rituximab in ANCA-associated Vasculitis Compared to the Originator
Recruiting NCT05383573 - Pediatric ANCA Associated-vasculitis
Completed NCT02222155 - Clinical Trial to Evaluate Safety and Efficacy of CCX168 in ANCA-Associated Vasculitis Phase 2
Recruiting NCT05197842 - Efficacy and Safety of Substitution of Glucocorticoid for BDB-001 Injection in Patients With Anti-neutrophil Cytoplasmic Antibody(ANCA)-Associated Vasculitis Phase 1/Phase 2
Completed NCT02954705 - MICRO-RNAs OF NEUTROPHILS IN RENAL ANTINEUTROPHIL CYTOPLASMIS ANTIBODY (ANCA) -ASSOCIATED VASCULITIS
Completed NCT04280601 - PRagmatic Analysis of Vitamin D in ANCA-Associated Vasculitis N/A
Active, not recruiting NCT02108860 - Abatacept for the Treatment of Relapsing, Non-Severe, Granulomatosis With Polyangiitis (Wegener's) Phase 3